A S F Doney1, B Fischer2, J E Cecil3, K Boylan2, F E McGuigan4, S H Ralston4, A D Morris5, C N A Palmer6. 1. Department of Clinical Pharmacology, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, UK. 2. Biomedical Research Centre, Ninewells Hospital and Medical School, Dundee, DD1 9SY, Scotland, UK. 3. Department of Psychology, University of Dundee, Dundee, Scotland, UK. 4. University of Aberdeen Medical School, Institute of Medical Sciences, Aberdeen, Scotland, UK. 5. Department of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, UK. 6. Biomedical Research Centre, Ninewells Hospital and Medical School, Dundee, DD1 9SY, Scotland, UK. colin.palmer@cancer.org.uk.
Abstract
AIMS/HYPOTHESIS: The Pro12Ala polymorphism of peroxisome proliferator-activated receptor (PPAR)gamma has been consistently associated with Type 2 diabetes. The rare Ala12 variant is estimated to reduce the risk of developing Type 2 diabetes by 20 percent. This variant is in linkage disequilibrium with another common variant, T1431. Both have opposing associations with body weight. We therefore examined the association of specific haplotypes marked by these two variants with susceptibility to Type 2 diabetes. METHODS: We determined the PPARG genotype of a large Scottish cohort of Type 2 diabetic patients ( n=1997) and compared allele frequencies with a cohort of local children ( n=2444) and a middle-aged, population-based cohort from Scotland ( n=1061). RESULTS: Frequency of the Ala12 allele was slightly lower in the Type 2 diabetic cohort than in the children [odds ratio (OR)=0.91, p=0.1]. In contrast, the Ala12 variant was under-represented in the Type 2 diabetic population when compared with similarly aged non-diabetic adults (OR=0.74, p=0.0006). When the Ala12 variant was on a haplotype not bearing the 1431T variant, it conferred greater protection (OR=0.66, p=0.003). However, when it was present in haplotypes containing the 1431T variant (70% of Ala12 carriers), this protection was absent (OR=0.99, p=0.94). CONCLUSIONS/ INTERPRETATION: We replicated the finding that the Ala12 variant of PPARgamma affords protection from Type 2 diabetes, and suggest that this protection is modulated by additional common variation at the PPARG locus.
AIMS/HYPOTHESIS: The Pro12Ala polymorphism of peroxisome proliferator-activated receptor (PPAR)gamma has been consistently associated with Type 2 diabetes. The rare Ala12 variant is estimated to reduce the risk of developing Type 2 diabetes by 20 percent. This variant is in linkage disequilibrium with another common variant, T1431. Both have opposing associations with body weight. We therefore examined the association of specific haplotypes marked by these two variants with susceptibility to Type 2 diabetes. METHODS: We determined the PPARG genotype of a large Scottish cohort of Type 2 diabeticpatients ( n=1997) and compared allele frequencies with a cohort of local children ( n=2444) and a middle-aged, population-based cohort from Scotland ( n=1061). RESULTS: Frequency of the Ala12 allele was slightly lower in the Type 2 diabetic cohort than in the children [odds ratio (OR)=0.91, p=0.1]. In contrast, the Ala12 variant was under-represented in the Type 2 diabetic population when compared with similarly aged non-diabetic adults (OR=0.74, p=0.0006). When the Ala12 variant was on a haplotype not bearing the 1431T variant, it conferred greater protection (OR=0.66, p=0.003). However, when it was present in haplotypes containing the 1431T variant (70% of Ala12 carriers), this protection was absent (OR=0.99, p=0.94). CONCLUSIONS/ INTERPRETATION: We replicated the finding that the Ala12 variant of PPARgamma affords protection from Type 2 diabetes, and suggest that this protection is modulated by additional common variation at the PPARG locus.
Authors: J Ek; G Andersen; S A Urhammer; L Hansen; B Carstensen; K Borch-Johnsen; T Drivsholm; L Berglund; T Hansen; H Lithell; O Pedersen Journal: Diabetologia Date: 2001-09 Impact factor: 10.122
Authors: Paul M Ridker; Nancy R Cook; Suzanne Cheng; Henry A Erlich; Klaus Lindpaintner; Jorge Plutzky; Robert Y L Zee Journal: Arterioscler Thromb Vasc Biol Date: 2003-03-27 Impact factor: 8.311
Authors: S S Deeb; L Fajas; M Nemoto; J Pihlajamäki; L Mykkänen; J Kuusisto; M Laakso; W Fujimoto; J Auwerx Journal: Nat Genet Date: 1998-11 Impact factor: 38.330
Authors: Francisco J Rodríguez-Esparragón; José C Rodríguez-Pérez; Antonio Macías-Reyes; Fayna Alamo-Santana Journal: J Hypertens Date: 2003-09 Impact factor: 4.844
Authors: Alex Doney; Bettina Fischer; David Frew; Alastair Cumming; David M Flavell; Michael World; Hugh E Montgomery; Douglas Boyle; Andrew Morris; Colin N A Palmer Journal: BMC Genet Date: 2002-11-13 Impact factor: 2.797
Authors: Samer Gawrieh; Miranda C Marion; Richard Komorowski; James Wallace; Michael Charlton; Ahmed Kissebah; Carl D Langefeld; Michael Olivier Journal: Dig Dis Sci Date: 2011-12-09 Impact factor: 3.199
Authors: Jose C Florez; Kathleen A Jablonski; Maria W Sun; Nick Bayley; Steven E Kahn; Harry Shamoon; Richard F Hamman; William C Knowler; David M Nathan; David Altshuler Journal: J Clin Endocrinol Metab Date: 2007-01-09 Impact factor: 5.958
Authors: Ulla Vogel; Stine Segel; Claus Dethlefsen; Anne Tjønneland; Anne Thoustrup Saber; Håkan Wallin; Majken K Jensen; Erik B Schmidt; Paal Skytt Andersen; Kim Overvad Journal: BMC Med Genet Date: 2009-06-07 Impact factor: 2.103